PE20170939A1 - Pirimidinonas como inhibidores del factor xia - Google Patents

Pirimidinonas como inhibidores del factor xia

Info

Publication number
PE20170939A1
PE20170939A1 PE2017000527A PE2017000527A PE20170939A1 PE 20170939 A1 PE20170939 A1 PE 20170939A1 PE 2017000527 A PE2017000527 A PE 2017000527A PE 2017000527 A PE2017000527 A PE 2017000527A PE 20170939 A1 PE20170939 A1 PE 20170939A1
Authority
PE
Peru
Prior art keywords
pyrimidinones
inhibitors
fxia
chloro
refers
Prior art date
Application number
PE2017000527A
Other languages
English (en)
Inventor
Andrew K Dilger
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Donald J P Pinto
Michael J Orwat
Ii Leon M Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20170939A1 publication Critical patent/PE20170939A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un derivado de pirimidinona de formula (I) donde A es un anillo de tipo a) o b); B es un anillo de tipo c) o d); R1 es H o alquilo C1-C4; R2 es H, F, entre otros; R3 es H, CHF2, entre otros; R4 es H o F; R5 es H, F, entre otros. Es un seleccionado: trifluoroacetato de (9R,13S)-13-{4-[5-cloro-2-(4-cloro-1H-1, 2, 3-triazol-1-il)fenil]-6-oxo-1, 6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3, 4, 7, 15-tetraazatriciclo[12.3.1.02.6]octadeca-1(18), 2(6), 4, 14, 16-pentaen-8-ona; entre otros. Tambien se refiere a una composicion farmaceutica. Dicho compuesto es un inhibidor selectivo del factor de coagulacion XIa (FXIa) o inhibidor dual de FXIa y calicreina plasmatica, siendo util para el tratamiento de trastornos tromboembolicos y/o inflamatorios
PE2017000527A 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia PE20170939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
PE20170939A1 true PE20170939A1 (es) 2017-07-13

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017000527A PE20170939A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia
PE2020001966A PE20210922A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020001966A PE20210922A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia

Country Status (33)

Country Link
EP (4) EP4286372A3 (es)
JP (4) JP6462865B2 (es)
KR (2) KR101921436B1 (es)
CN (3) CN106795161B (es)
AR (1) AR101367A1 (es)
AU (3) AU2015324530B2 (es)
CA (1) CA2963395C (es)
CL (1) CL2017000712A1 (es)
CO (1) CO2017003833A2 (es)
CY (2) CY1119678T1 (es)
DK (2) DK3293186T3 (es)
EA (1) EA031590B1 (es)
ES (3) ES2963267T3 (es)
HR (2) HRP20171950T1 (es)
HU (2) HUE052812T2 (es)
IL (2) IL251434B (es)
LT (2) LT3293186T (es)
MA (1) MA40123A1 (es)
MX (2) MX2017003695A (es)
MY (1) MY183987A (es)
NO (1) NO2721243T3 (es)
PE (2) PE20170939A1 (es)
PH (2) PH12017500580A1 (es)
PL (1) PL3089979T3 (es)
PT (2) PT3089979T (es)
RS (2) RS61183B1 (es)
SG (2) SG10201911652TA (es)
SI (2) SI3293186T1 (es)
TN (2) TN2017000112A1 (es)
TW (3) TWI692478B (es)
UY (1) UY36244A (es)
WO (1) WO2016053455A1 (es)
ZA (1) ZA201702478B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
NO2760821T3 (es) 2014-01-31 2018-03-10
RS57659B1 (sr) * 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
JP6662865B2 (ja) 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (es) * 2014-10-01 2018-10-20
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
WO2017019821A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia new macrocycle bearing a non-aromatic p2' group
JP6629958B2 (ja) * 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110062757B (zh) * 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200604A1 (es) 2017-05-22 2020-03-10 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
ES2969253T3 (es) * 2019-04-11 2024-05-17 Bristol Myers Squibb Co Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona
BR112021020257A2 (pt) * 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
AU2020257911B2 (en) * 2019-04-16 2023-01-05 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
WO2021057818A1 (zh) * 2019-09-27 2021-04-01 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途
CN115916780A (zh) * 2020-04-10 2023-04-04 百时美施贵宝公司 (9r,13s)-13-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代-1,6-二氢嘧啶-1-基}-3-(二氟甲基)-9-甲基-3,4,7,15-四氮杂三环[12.3.1.02,6]十八-1(18),2(6),4,14,16-五烯-8-酮的晶型
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
EP4274854A1 (en) 2021-01-08 2023-11-15 Bristol-Myers Squibb Company Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
CN115215867B (zh) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
EP3786165A1 (en) * 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Synthetic intermediates for producing macrocycles as factor xia inhibitors
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US9327839B2 (en) 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
CA2859604C (en) * 2011-12-21 2019-12-17 Ono Pharmaceutical Co., Ltd. Compounds
EA028581B1 (ru) * 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
EA025392B1 (ru) * 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia
RS57659B1 (sr) * 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
NO2760821T3 (es) * 2014-01-31 2018-03-10
NO2721243T3 (es) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
KR102269999B1 (ko) 2021-06-25
NZ731416A (en) 2024-01-26
TW202310844A (zh) 2023-03-16
JP7317905B2 (ja) 2023-07-31
EA201790595A1 (ru) 2017-07-31
EP4286372A3 (en) 2024-02-21
CL2017000712A1 (es) 2017-11-03
CA2963395C (en) 2023-03-14
EP3089979B1 (en) 2017-10-18
NO2721243T3 (es) 2018-10-20
IL251434A0 (en) 2017-05-29
EP3828186A3 (en) 2021-07-28
KR20180126612A (ko) 2018-11-27
HUE052812T2 (hu) 2021-05-28
ES2836270T3 (es) 2021-06-24
TWI834182B (zh) 2024-03-01
MX2017003695A (es) 2017-05-30
MA40123A1 (fr) 2017-09-29
TWI692478B (zh) 2020-05-01
RS61183B1 (sr) 2021-01-29
UY36244A (es) 2016-01-29
ES2963267T3 (es) 2024-03-26
EP4286372A2 (en) 2023-12-06
CN106795161B (zh) 2019-10-15
MY183987A (en) 2021-03-17
PH12020500195A1 (en) 2021-02-08
AU2015324530B2 (en) 2019-10-24
MX2020010840A (es) 2020-11-06
PH12017500580B1 (en) 2017-08-30
AU2020200376B2 (en) 2021-07-08
EP3828186B1 (en) 2023-08-23
IL276470B (en) 2021-04-29
TN2018000229A1 (en) 2019-10-04
JP6462865B2 (ja) 2019-01-30
CA2963395A1 (en) 2016-04-07
WO2016053455A1 (en) 2016-04-07
PH12017500580A1 (en) 2017-08-30
EA031590B1 (ru) 2019-01-31
HUE038061T2 (hu) 2018-09-28
AU2021245098A1 (en) 2021-10-28
JP2021185182A (ja) 2021-12-09
CN114957255A (zh) 2022-08-30
TW201613923A (en) 2016-04-16
AU2021245098B2 (en) 2023-11-23
CY1119678T1 (el) 2018-04-04
JP6937734B2 (ja) 2021-09-22
TWI769442B (zh) 2022-07-01
PT3293186T (pt) 2020-12-09
TN2017000112A1 (en) 2018-07-04
LT3089979T (lt) 2017-12-27
KR101921436B1 (ko) 2018-11-22
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
CN110734435A (zh) 2020-01-31
BR112017006702A2 (pt) 2017-12-26
NZ766570A (en) 2024-01-26
PT3089979T (pt) 2018-01-16
RS56786B1 (sr) 2018-04-30
SG11201702576QA (en) 2017-04-27
ZA201702478B (en) 2019-06-26
IL276470A (en) 2020-09-30
HRP20201927T1 (hr) 2021-02-05
SI3089979T1 (sl) 2017-12-29
DK3089979T3 (en) 2018-01-15
JP2023134734A (ja) 2023-09-27
JP2017530157A (ja) 2017-10-12
KR20170057431A (ko) 2017-05-24
TW202043228A (zh) 2020-12-01
EP3293186B1 (en) 2020-09-23
CN110734435B (zh) 2022-06-07
PL3089979T3 (pl) 2018-02-28
JP2019069989A (ja) 2019-05-09
ES2655884T3 (es) 2018-02-22
CN106795161A (zh) 2017-05-31
CY1123663T1 (el) 2022-03-24
LT3293186T (lt) 2020-12-28
SG10201911652TA (en) 2020-02-27
DK3293186T3 (da) 2020-12-14
EP3293186A1 (en) 2018-03-14
EP3828186A2 (en) 2021-06-02
AU2015324530A1 (en) 2017-05-18
PE20210922A1 (es) 2021-05-19
HRP20171950T1 (hr) 2018-02-23
IL251434B (en) 2020-08-31
SI3293186T1 (sl) 2021-01-29
AR101367A1 (es) 2016-12-14
AU2020200376A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
PH12021550418A1 (en) Macrocycles with hetrocyclic p2` groups as factor xia inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
CY1120534T1 (el) Μακροκυκλικοι αναστολεις παραγοντα χια συμπυκνωμενοι με ετεροκυκλους
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
PH12016501388A1 (en) Heteroaryls and uses thereof
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
EA201691302A1 (ru) Новые гетероциклические соединения
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
PH12017500595A1 (en) Aldosterone synthase inhibitors
BR112017028577A2 (pt) forma cristalina de um maleato do derivado de piridina fundida e usos da mesma
EA202191885A2 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4